672325-23-4

Usage

Uses

3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 6,6-dimethyl-, methyl ester, (1R,2S,5S)-(9CI) may be used in various applications across different industries, pending further research and testing to determine its exact properties and utility. Some potential uses include:
Used in Organic Synthesis:
3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 6,6-dimethyl-, methyl ester, (1R,2S,5S)-(9CI) is used as a building block or intermediate in organic synthesis for the creation of more complex molecules, leveraging its unique structure and stereochemistry.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 6,6-dimethyl-, methyl ester, (1R,2S,5S)-(9CI) may be utilized as an active pharmaceutical ingredient or as a key component in the development of new drugs, given its potential to interact with biological targets due to its specific stereochemistry.
Used in Chemical Research:
3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 6,6-dimethyl-, methyl ester, (1R,2S,5S)-(9CI) is used as a research compound in chemical studies to explore its reactivity, properties, and potential applications in various chemical processes.

Upstream product

• 67-56-1 methanol 
• 1037559-82-2 (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carbonitrile 
• 943516-54-9 6,6-dimethyl-3-azabicyclo[3.1.0]hexane 
• 911835-76-2 (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylic acid 

Downstream Products

• 394735-26-3 (1R,2S,5S)-3-((S)-2-tert-Butoxycarbonylamino-3,3-dimethyl-butyryl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid methyl ester 
• 951789-91-6 C₂₃H₃₈N₂O₅ 
• 394735-24-1 (1R,2S,5S)-3-((S)-2-tert-Butoxycarbonylamino-2-cyclohexyl-acetyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Efficient, chemoenzymatic process for manufacture of the boceprevir bicyclic [3.1.0]proline intermediate based on amine oxidase-catalyzed desymmetrization

The key structural feature in Boceprevir, Merck's new drug treatment for hepatitis C, is the bicyclic [3.1.0]proline moiety "P2". During the discovery and development stages, the P2 fragment was produced by a classical resolution approach. As the drug candidate advanced through clinical trials and approached regulatory approval and commercialization, Codexis and Schering-Plough (now Merck) jointly developed a chemoenzymatic asymmetric synthesis of P2 where the net reaction was an oxidative Strecker reaction. The key part of this reaction sequence is an enzymatic oxidative desymmetrization of the prochiral amine substrate.

AN IMPROVED PROCESS FOR THE PREPARATION OF RACEMIC 6, 6- DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE AND ITS SALTS, A KEY RAW MATERIAL FOR HCV INHIBITOR.

The present invention discloses an efficient and economical process for the preparation of racemic 6, 6-dimethyl-3-azabicyclo-[3.1.0]-hexane of formula I and its salts. The invention relates to the compounds of formulae I and II. The compound of formula I

PROCESS AND INTERMEDIATES FOR THE PREPARATION OF (1R,2S,5S)-6,6-DIMETHYL-3-AZABICYCLO[3,1,0]HEXANE-2-CARBOXYLATES OR SALTS THEREOF

In one embodiment, the present application relates to a process of making a compound of Formula (I); and to certain intermediate compounds that are made within the process of making the compound Formula (I).

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.